rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Jade Biosciences, Inc.

JBIO · Nasdaq

Health CareBiotechnologyNot moving yet

JBIO stood above a rising 150-day average in 35 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 28.7% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
147 (+33)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 35 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$43KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders147+33 on the quarter
New · exited50 · 16
Reported value$1.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 20269,126,877$202.8M+2,041,454+28.8%
Jupiter Topco LLCnew · filed 14 Aug 20266,273,262$139.4M+6,273,262
Fairmount Funds Management LLCunchanged · filed 14 Aug 20264,553,494$101.2M00.0%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20263,671,083$81.6M00.0%
Venrock Adviser, LLCunchanged · filed 14 Aug 20263,220,364$71.6M00.0%
Bellevue Group AGreduced · filed 14 Aug 20263,057,996$67.9M-443,506−12.7%
Paradigm Biocapital Advisors LPnew · filed 14 Aug 20262,857,405$63.5M+2,857,405
BlackRock, Inc.added · filed 7 Aug 20262,801,451$62.2M+487,502+21.1%
FRANKLIN RESOURCES INCnew · filed 13 Aug 20262,792,080$62.0M+2,792,080
STATE STREET CORPadded · filed 7 Aug 20262,335,285$51.9M+1,679,595+256.2%
30 Jun 2025 – 30 Jun 2026
69107144Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Mark Eisner Company insiderDirector · last 25 Jun 20260 · 0
Christopher W. Cain Company insiderDirector · last 9 Jun 20260 · 0
Eric Dobmeier Company insiderDirector · last 9 Jun 20260 · 0
Erin Lavelle Company insiderDirector · last 9 Jun 20260 · 0
Fairmount Funds Management LLC Company insiderDirector, 10% owner · last 9 Jun 20260 · 0
Lawrence Otto Klein Company insiderDirector · last 9 Jun 20260 · 0
Tomas Kiselak Company insiderDirector, 10% owner · last 9 Jun 20260 · 0
Andrew James King Company insiderOfficer · last 12 Feb 20260 · 0
Bradford D. Dahms Company insiderChief Financial Officer · last 12 Feb 20260 · 0
Elizabeth Balta Company insiderOfficer · last 12 Feb 20260 · 0
Tom Frohlich Company insiderChief Executive Officer · last 12 Feb 20261 · 0
Fairmount Healthcare Fund Ii L.p. Company insiderDirector, 10% owner · last 6 Oct 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-34.1%
Share count trendFY 2025 · to 28 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$88.4M
Free cash flowFY 2025 · to 31 Dec 2025−$94.9M

Analyst forecasts

No analyst forecasts yet.